mochi health compounded tirzepatide Eli Lilly sues and others for 'deceptive' marketing eli lilly sues compounders for

doi: 10.1016/j.molmet.2021.101180 209 KellyPMcCleanPLAckermannMKonerdingMAHolscherCMitchellCA

(PubMed) Lee BC, Peterfi Z, Hoffmann FW, et al

Women experiencing bleeding after menopause should contact their doctor for evaluation

This study shows that tirzepatide, a drug that activates GIP and GLP-1 receptors, can directly affect fat cells by increasing their ability to take up and store nutrients when insulin is present (fed state) and promoting fat breakdown when insulin is low (fasted state)

In an embodiment, there is provided a method of providing therapeutic weight loss comprising administering to a human in need thereof an effective amount of a compositions comprising 40 mg/mL tirzepatide, or a pharmaceutically acceptable salt thereof